{"entity":{"id":"nct05636215","kind":"trial","name":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IBI354 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05636215 by Innovent Biologics (Suzhou) Co. Ltd., with 368 participants planned, started 2023-04-04 and due to reach its primary completion in 2025-04-30. Interventions recorded: IBI354.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05636215","url":"https://clinicaltrials.gov/study/NCT05636215"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi354"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05636215","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":368,"outcomes":[]},"route":"/trials/nct05636215/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/"}]}}